Bcl-2 Protein Expression and Prognosis in Colorectal Cancer
Author Information
Author(s): L Kaklamanis, A Savage, R Whitehouse, I Doussis-Anagnostopoulou, S Biddolph, P Tsiotos, N Mortensen, KC Gatter, AL Harris
Primary Institution: University of Oxford
Hypothesis
Is there an association between Bcl-2 protein expression, p53 expression, and prognosis in colorectal cancer?
Conclusion
Bcl-2 expression is associated with better prognosis in early-stage colorectal cancer, particularly in patients with negative p53 status.
Supporting Evidence
- Bcl-2 expression was down-regulated in 67% of colorectal carcinoma cases compared to normal mucosa.
- Patients with p53-positive cases had significantly worse survival outcomes.
- Bcl-2-positive patients showed a slightly better prognosis, particularly in early Dukes' stages.
- Statistical analysis revealed significant differences in survival based on combined bcl-2 and p53 status.
Takeaway
This study looked at how a protein called Bcl-2 affects survival in colorectal cancer. It found that patients with Bcl-2 are more likely to do better, especially if they don't have a problem with another protein called p53.
Methodology
The study analyzed tissue samples from 224 colorectal cancer patients, assessing Bcl-2 and p53 expression using immunohistochemistry and correlating these with survival data.
Limitations
The study did not include patients who died from causes unrelated to their disease within the first month, which may affect survival analysis.
Participant Demographics
Median age of participants was 67 years, with a mix of males and females.
Statistical Information
P-Value
0.01
Confidence Interval
95% CI 0.61-2.38 for bcl-2 status
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website